Co-workers

In current position since 2019, employed since 2011.

Education: Secondary school economics 1989, graduate in accounting 1999, certified controller 2021.

Experience and prior assignments: Carina Eldh has more than 20 years of experience in accounting, auditing and taxation and has previously held positions at KPMG and other auditing and advisory firms, the Swedish Tax Agency and Öresundskraft.

Other current assignments: –

Born: 1970

Holdings: 9,900 shares* and 20,000 warrants**.

In current position since 2023.

Education: M.Sc. in Pharmacy in 2000 from the Faculty of Pharmaceutical Sciences, University of Copenhagen.

Experience and prior assignments: René Egebro has more than 23 years of experience from senior positions in Chemical, Manufacturing & Control from pre-clinical development to late-stage clinical development. René has a broad experience as Senior Director and CMC outsourcing manager in managing International CMOs for the development, manufacture, formulation and analysis of cGMP Drug Substances and Drug Products. René has held positions at Novo Nordisk, Lundbeck, NeuroSearch and several small biotech leading CMC development, ensuring progress and oversight of multiple development programs, providing strategic advice on CMC development, and representing the company in front of FDA and other regulatory authorities.

Other current assignments: –

Born: 1974

Holdings: –

In current position since 2022.

Education: Master of Medicine in Pharmaceutical Bioscience, Gothenburg University, PhD in Medical Inflammation Research, Lund University.

Experience and prior assignments: Malin Hultqvist Hopkins has more than 15 years of experience in R&D and early drug discovery. She has held several operational roles at Redoxis AB, including Project Leader Drug Discovery, Director of CRO Studies and since 2016 she is the CEO of the company. Redoxis offers preclinical services. Malin holds a genuine experience in immunology and preclinical models of inflammation and autoimmunity.

Other current assignments: Board member of Redoxis AB and ProNoxis AB.

Born: 1979

Holdings: 7,950 shares*.

In current position since 2019.

Education: Ph.D. in Organic Chemistry 2002, Associate Professor in Organic Chemistry 2007, and Master’s degree in Chemical Engineering 1997, Lund University.

Experience and prior assignments: Martin Johansson has been involved with Aqilion since 2012 as project manager for the former project company Glactone Pharma AB. He has 20 years of experience in medicinal chemistry and preclinical drug discovery and development. Previously, he has held the position of Chief Scientific Officer at Respiratorius AB and Senior Research Scientist at AstraZeneca, Discovery R&D.

Other current assignments: –

Born: 1971

Holdings: 21,000 shares* and 24,100 warrants**.

In current position since 2023.

Education: Ph.D. in Biochemistry/Immunology 1998 from Imperial College, London.

Experience and prior assignments: Wayne Russell has more than 18 years of experience from the pharmaceutical industry, covering all aspects of the R&D pipeline from target identification to clinical development and external innovation evaluation. He has held positions at AstraZeneca, LEO Pharma and Zealand Pharma, working in dermatology, gastrointestinal and metabolic, inflammation, and respiratory therapeutic areas. More recently Wayne worked in the Innovation office at Lund University.

Other current assignments: –

Born: 1972

Holdings: 21,011 warrants**.

In current position since 2022.

Education: Bachelor of Medical Science in Medical Biology, Linköping University, studies in clinical drug development at Uppsala University.

Experience and prior assignments: Anneli Tinnerholm has more than 10 years of experience from clinical trials as Clinical Research Associate and Clinical Trial Project Manager. She has held several operational positions in the CRO companies NORMA and LINK Medical, followed by an advisory clinical project management role at SDS Life Science with focus on smaller pharma and biotech companies. Anneli has gained a broad competence within clinical operations from FIH (first in humans) and Phase I to Phase IV clinical trials in several indications and therapy areas.

Other current assignments: –

Born: 1986

Holdings: 4,550 shares* and 21,011 warrants**.

In current position since 2018.

Education: Medical degree, University of Gothenburg, 1985; Ph.D. in Physiology, Faculty of Medicine, Gothenburg, 1990; and Associate Professor in Physiology, 1992.

Experience and prior assignments: Jan Törnell has been involved with Aqilion/P.U.L.S. since 2012 through board positions in portfolio companies, as project manager/CEO and as an innovator. He also has many years of experience in executive positions in the pharmaceutical industry internationally. He has previously held the position of Global Vice President Strategy, Oncology & Infection and Global VP Translational Science at AstraZeneca and was Professor at the Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg.

Other current assignments: Chairman of the Board of Glactone Pharma AB, and Innoext AB; Board member of Abliva AB
(publ).

Born: 1960

Holdings: 7,644 shares* and 21,011 warrants**.

In current position since 2023.

Education: Master of Medical Science in Medical Biology, Linköping University, studies in clinical drug development at Uppsala University.

Experience and prior assignments: Anna-Mia has more than 10 years of experience within the quality area. She started her career at a small pharmaceutical company as quality manager and later she joined the Swedish Clinical Team at the global pharmaceutical company Novo Nordisk. During her years at Novo Nordisk she gained a broad experience within clinical operations with focus on Phase III clinical trials in several indications and therapy areas. She has previously held the position as project manager at the Coordination Council of Neurology, Region Västra Götaland.

Other current assignments: –

Born: 1984

Holdings: 21,011 warrants**.